Aerovate Therapeutics Financials
| AVTE Stock | USD 2.64 0.04 1.49% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.69 | 7.0438 |
|
|
Investors should never underestimate Aerovate Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aerovate Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Aerovate Therapeutics.
Net Income |
|
Aerovate | Select Account or Indicator |
Understanding current and past Aerovate Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aerovate Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Aerovate Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Aerovate Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aerovate Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aerovate Therapeutics' management manipulating its earnings.
Aerovate Therapeutics Stock Summary
Aerovate Therapeutics competes with Ikena Oncology, Eliem Therapeutics, HCW Biologics, Tempest Therapeutics, and Scpharmaceuticals. Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Aerovate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US0080641071 |
| CUSIP | 008064107 |
| Location | Massachusetts; U.S.A |
| Business Address | 930 Winter Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | aerovatetx.com |
| Phone | 617 443 2400 |
| Currency | USD - US Dollar |
Aerovate Therapeutics Key Financial Ratios
| Return On Equity | -0.82 | ||||
| EBITDA | (81.31 M) | ||||
| Net Income | (75.52 M) | ||||
| Cash Per Share | 6.22 X | ||||
| Debt To Equity | 0.01 % |
Aerovate Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aerovate Therapeutics's current stock value. Our valuation model uses many indicators to compare Aerovate Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aerovate Therapeutics competition to find correlations between indicators driving Aerovate Therapeutics's intrinsic value. More Info.Aerovate Therapeutics is rated third in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Aerovate Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aerovate Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Aerovate Therapeutics Systematic Risk
Aerovate Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aerovate Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Aerovate Therapeutics correlated with the market. If Beta is less than 0 Aerovate Therapeutics generally moves in the opposite direction as compared to the market. If Aerovate Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aerovate Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aerovate Therapeutics is generally in the same direction as the market. If Beta > 1 Aerovate Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Aerovate Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aerovate Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aerovate Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Aerovate Therapeutics November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aerovate Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aerovate Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aerovate Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Aerovate Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aerovate Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.53 | |||
| Information Ratio | 0.1261 | |||
| Maximum Drawdown | 19.11 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 5.58 |
Complementary Tools for Aerovate Stock analysis
When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |